FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386150862> ?p ?o ?g. }

• W4386150862 endingPage "3682" @default.
• W4386150862 startingPage "3672" @default.
• W4386150862 abstract "Abstract Background and Aims In the ADVOR trial, acetazolamide improved decongestion in acute decompensated heart failure (ADHF). Whether the beneficial effects of acetazolamide are consistent across the entire range of renal function remains unclear. Methods This is a pre-specified analysis of the ADVOR trial that randomized 519 patients with ADHF to intravenous acetazolamide or matching placebo on top of intravenous loop diuretics. The main endpoints of decongestion, diuresis, natriuresis, and clinical outcomes are assessed according to baseline renal function. Changes in renal function are evaluated between treatment arms. Results On admission, median estimated glomerular filtration rate (eGFR) was 40 (30–52) mL/min/1.73 m². Acetazolamide consistently increased the likelihood of decongestion across the entire spectrum of eGFR (P-interaction = .977). Overall, natriuresis and diuresis were higher with acetazolamide, with a higher treatment effect for patients with low eGFR (both P-interaction &lt; .007). Acetazolamide was associated with a higher incidence of worsening renal function (WRF; rise in creatinine ≥ 0.3 mg/dL) during the treatment period (40.5% vs. 18.9%; P &lt; .001), but there was no difference in creatinine after 3 months (P = .565). This was not associated with a higher incidence of heart failure hospitalizations and mortality (P-interaction = .467). However, decongestion at discharge was associated with a lower incidence of adverse clinical outcomes irrespective of the onset of WRF (P-interaction = .805). Conclusions Acetazolamide is associated with a higher rate of successful decongestion across the entire range of renal function with more pronounced effects regarding natriuresis and diuresis in patients with a lower eGFR. While WRF occurred more frequently with acetazolamide, this was not associated with adverse clinical outcomes. ClinicalTrials.gov Identifier NCT03505788." @default.
• W4386150862 created "2023-08-26" @default.
• W4386150862 creator A5005788624 @default.
• W4386150862 creator A5013727186 @default.
• W4386150862 creator A5023320363 @default.
• W4386150862 creator A5026254558 @default.
• W4386150862 creator A5032967663 @default.
• W4386150862 creator A5035023430 @default.
• W4386150862 creator A5046318945 @default.
• W4386150862 creator A5049111204 @default.
• W4386150862 creator A5051270747 @default.
• W4386150862 creator A5055597403 @default.
• W4386150862 creator A5076729702 @default.
• W4386150862 creator A5082623751 @default.
• W4386150862 creator A5086624399 @default.
• W4386150862 creator A5088059687 @default.
• W4386150862 date "2023-08-25" @default.
• W4386150862 modified "2023-10-16" @default.
• W4386150862 title "Renal Function and Decongestion With Acetazolamide in Acute Decompensated Heart Failure: The ADVOR Trial" @default.
• W4386150862 cites W1969091056 @default.
• W4386150862 cites W2038334551 @default.
• W4386150862 cites W2054965274 @default.
• W4386150862 cites W2078762775 @default.
• W4386150862 cites W2104547465 @default.
• W4386150862 cites W2114588585 @default.
• W4386150862 cites W2139359396 @default.
• W4386150862 cites W2155965977 @default.
• W4386150862 cites W2165668878 @default.
• W4386150862 cites W2299836127 @default.
• W4386150862 cites W2465112930 @default.
• W4386150862 cites W2590523744 @default.
• W4386150862 cites W2766498687 @default.
• W4386150862 cites W2784257687 @default.
• W4386150862 cites W2883174777 @default.
• W4386150862 cites W2890636056 @default.
• W4386150862 cites W2907983377 @default.
• W4386150862 cites W3000607175 @default.
• W4386150862 cites W3025899746 @default.
• W4386150862 cites W3106776335 @default.
• W4386150862 cites W3213007181 @default.
• W4386150862 cites W34259112 @default.
• W4386150862 cites W4226061733 @default.
• W4386150862 cites W4283320810 @default.
• W4386150862 cites W4293872386 @default.
• W4386150862 cites W4306684314 @default.
• W4386150862 cites W4309908777 @default.
• W4386150862 cites W4368356880 @default.
• W4386150862 cites W4377164037 @default.
• W4386150862 doi "https://doi.org/10.1093/eurheartj/ehad557" @default.
• W4386150862 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37623428" @default.
• W4386150862 hasPublicationYear "2023" @default.
• W4386150862 type Work @default.
• W4386150862 citedByCount "1" @default.
• W4386150862 countsByYear W43861508622023 @default.
• W4386150862 crossrefType "journal-article" @default.
• W4386150862 hasAuthorship W4386150862A5005788624 @default.
• W4386150862 hasAuthorship W4386150862A5013727186 @default.
• W4386150862 hasAuthorship W4386150862A5023320363 @default.
• W4386150862 hasAuthorship W4386150862A5026254558 @default.
• W4386150862 hasAuthorship W4386150862A5032967663 @default.
• W4386150862 hasAuthorship W4386150862A5035023430 @default.
• W4386150862 hasAuthorship W4386150862A5046318945 @default.
• W4386150862 hasAuthorship W4386150862A5049111204 @default.
• W4386150862 hasAuthorship W4386150862A5051270747 @default.
• W4386150862 hasAuthorship W4386150862A5055597403 @default.
• W4386150862 hasAuthorship W4386150862A5076729702 @default.
• W4386150862 hasAuthorship W4386150862A5082623751 @default.
• W4386150862 hasAuthorship W4386150862A5086624399 @default.
• W4386150862 hasAuthorship W4386150862A5088059687 @default.
• W4386150862 hasBestOaLocation W43861508621 @default.
• W4386150862 hasConcept C126322002 @default.
• W4386150862 hasConcept C126894567 @default.
• W4386150862 hasConcept C159641895 @default.
• W4386150862 hasConcept C164705383 @default.
• W4386150862 hasConcept C174459258 @default.
• W4386150862 hasConcept C2777405951 @default.
• W4386150862 hasConcept C2778198053 @default.
• W4386150862 hasConcept C2779295919 @default.
• W4386150862 hasConcept C2779547328 @default.
• W4386150862 hasConcept C2780306776 @default.
• W4386150862 hasConcept C2780472472 @default.
• W4386150862 hasConcept C71924100 @default.
• W4386150862 hasConceptScore W4386150862C126322002 @default.
• W4386150862 hasConceptScore W4386150862C126894567 @default.
• W4386150862 hasConceptScore W4386150862C159641895 @default.
• W4386150862 hasConceptScore W4386150862C164705383 @default.
• W4386150862 hasConceptScore W4386150862C174459258 @default.
• W4386150862 hasConceptScore W4386150862C2777405951 @default.
• W4386150862 hasConceptScore W4386150862C2778198053 @default.
• W4386150862 hasConceptScore W4386150862C2779295919 @default.
• W4386150862 hasConceptScore W4386150862C2779547328 @default.
• W4386150862 hasConceptScore W4386150862C2780306776 @default.
• W4386150862 hasConceptScore W4386150862C2780472472 @default.
• W4386150862 hasConceptScore W4386150862C71924100 @default.
• W4386150862 hasFunder F4320336788 @default.
• W4386150862 hasIssue "37" @default.
• W4386150862 hasLocation W43861508621 @default.
• W4386150862 hasLocation W43861508622 @default.

• next